Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharma.2011.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
Mult Scler
January 2025
NYU MS Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
Background: In the DISCOMS (DISCOntinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS)) randomized clinical trial, we could not demonstrate that discontinuing MS DMTs in older, stable adults was not inferior to continuing DMTs. Relapses were rare in both groups, and most new disease activity was one to two new brain magnetic resonance imaging (MRI) lesions unassociated with clinical changes.
Objective/aims: Describe results of the DISCOMS extension study.
Annals for Hospitalists - January 2025.
Ann Intern Med
January 2025
From University of Michigan, Ann Arbor, Michigan (D.A.F.).
Annals Consult Guys - Measuring Body Temperature: A Hot Topic?
Ann Intern Med
January 2025
University of Maryland and VA Maryland Health Care System, Baltimore, Maryland (P.A.M.).
Annals On Call - Diagnostic Reasoning Part 2.
Ann Intern Med
January 2025
Tufts University School of Medicine, Wellesley, Massachusetts (J.P.K.).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!